Abstract:The proinflammatory cytokine tumor necrosis factor-alpha (TNFα) exists naturally in two forms, a 26 kDa transmembrane form (TM-TNFα), and a 17 kDa secretory form (S-TNFα). The biological roles for each of these forms of TNFα in tumor killing have not been completely elucidated. Therefore, in this study, three different recombinant retroviral vectors, wild-type TNFα, solely secretable TNFα mutant, and uncleavable transmembrane TNFα mutant, were constructed by molecular techniques and stably transfected into a murine hepatic carcinoma cell line (H22). TNFα, either secreted in cell culture supernatants by secretable TNFα mutant- or wild-type TNFα-producing tumor cells, or as a treansmembrane form expressed on the cell surface of uncleavable TNFα mutant- or wild-type TNFα-synthesizing tumor cells, was demonstrated to be cytotoxic against the TNF sensitive L929 cell line. The H22 cells transfected with the three different forms of TNFα were shown to kill parental H22 cells in an in vitro cytotoxicity assay [effect/target (E/T) ratio-dependent manner], and their maximal killing rates were ~38–43% at E/T ratio of 5:1. The injection of total 2.5×105 mixed cells containing transfected and parental H22 tumor cells at different ratios into syngeneic mice resulted in the inhibition of tumor growth with a maximal inhibition rates of ~57~72% at E/T ratio of 5:1. A transient weight loss was found in mice bearing solely secretable TNFα mutant producing tumors, whereas no obvious side effects were seen in mice bearing uncleavable TNFα mutant or wild-type TNFα expressing tumors. Finally, we demonstrate that tumors secreting S-TNFα promoted the subsequent infiltration of CD4+ T cells, and to a lesser extent CD8+ T cells, to the tumor site. The TM-TNFα expressing tumors up-regulated Fas (CD95) expression and inhibited the expression of tumor metastasis associated molecule CD44v3. These results suggest that S-TNFα and TM-TNFα kill cancer cells in vivo through different mechanisms of action. We conclude that the non-secreted form of TNFα may be an ideal candidate for cancer gene therapy due to its therapeutic potential and lowered side effect profile.

Tumor Necrosis Factor Receptor 2-Mediated Tumor Suppression is Nitric Oxide Dependent and Involves Angiostasis.

Effects of antioxidants and NO on TNF-α-induced adhesion molecule expression in human pulmonary microvascular endothelial cells

Direct Demonstration Of Negative Regulation Of Tumor Growth And Metastasis By Host-Inducible Nitric Oxide Synthase

Transmembrane TNF-A Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2

The Emerging Roles of Nitric Oxide in Ferroptosis and Pyroptosis of Tumor Cells.

[The Role of Nitric Oxide in the Cytotoxic Effect of Macrophages].

Dual Roles of Tumor Necrosis Factor-Α Receptor-1 in a Mouse Model of Hindlimb Ischemia

Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response Via Inducing CD8+ T Cell Infiltration.

TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors

Tumor Necrosis Factor-Alpha Promotes Tumor Growth by Inducing Vascular Endothelial Growth Factor

Forward and Reverse Signaling Mediated by Transmembrane Tumor Necrosis Factor-Alpha and TNF Receptor 2: Potential Roles in an Immunosuppressive Tumor Microenvironment

Mechanism of Action Differences in the Antitumor Effects of Transmembrane and Secretory Tumor Necrosis Factor-Alpha in Vitro and in Vivo.

Mechanism of TNF-a acting on cerebrovascular endothelial cells and producing pathological nitric oxide

Low-dose TNF-α Promotes Angiogenesis of Oral Squamous Cell Carcinoma Cells Via TNFR2/Akt/mTOR Axis.

Angiopoietin-2 promotes inflammatory lymph angiogenesis and its effect can be blocked by the specific inhibitor L1-10

Activation of JNK and xanthine oxidase by TNF-alpha impairs nitric oxide-mediated dilation of coronary arterioles

Nitric Oxide Regulates Th1 Cell Development Through the Inhibition of IL-12 Synthesis by Macrophages.

Transmembrane Tumor Necrosis Factor-Α Promotes the Recruitment of MDSCs to Tumor Tissue by Upregulating CXCR4 Expression Via TNFR2

Dual Regulation Of Soluble Tumor Necrosis Factor-Alpha Induced Activation Of Human Monocytic Cells Via Modulating Transmembrane Tnf-Alpha-Mediated 'Reverse Signaling'

Exogenous, but not Endogenous Nitric Oxide Inhibits Adhesion Molecule Expression in Human Endothelial Cells

TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling